Tazemetostat: An FDA-approved EZH2 inhibitor for epithelioid sarcoma, tazemetostat reduces H3K27me3 levels in GBM cells by 70% and blocks PMT in PN-type GICs [113]. This evidence concerns the gene EZH2 and glioblastoma.